WVE
NASDAQWave Life Sciences Ltd.
Price$3.10-0.10 (-3.27%)
01:30 PM04:30 PM
News · 26 weeks76+1700%
2026-04-192026-10-11
Mix5390d
- SEC Filings21(40%)
- Other13(25%)
- Insider12(23%)
- Analyst4(8%)
- Earnings2(4%)
- Leadership1(2%)
Latest news
25 items- ANALYSTWilliam Blair initiated coverage on Wave Life SciencesWilliam Blair initiated coverage of Wave Life Sciences with a rating of Outperform
- ANALYSTUBS initiated coverage on Wave Life Sciences with a new price targetUBS initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $11.00
- SECSEC Form DEF 14A filed by Wave Life Sciences Ltd.DEF 14A - Wave Life Sciences, Inc. (0001631574) (Filer)
- PRWave Life Sciences to Present at Chardan’s 10th Annual Healthcare ConferenceCAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in the "RNA Medicines: Next-Generation RNA Therapeutics" panel at Chardan’s 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026 at 9:45 a.m. ET. A live webcast of the panel can be accessed by visiting "Investor Events" on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A repl
- INSIDERSEC Form 4 filed by Wave Life Sciences Ltd.4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- INSIDERSEC Form 4 filed by Wave Life Sciences Ltd.4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- INSIDERSEC Form 4 filed by Wave Life Sciences Ltd.4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- INSIDERSEC Form 4 filed by Wave Life Sciences Ltd.4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- INSIDERSEC Form 4 filed by Wave Life Sciences Ltd.4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- INSIDERSEC Form 4 filed by Wave Life Sciences Ltd.4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- INSIDERSEC Form 4 filed by Wave Life Sciences Ltd.4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- INSIDERSEC Form 4 filed by Wave Life Sciences Ltd.4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- ANALYSTLadenburg Thalmann initiated coverage on Wave Life Sciences with a new price targetLadenburg Thalmann initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $10.00
- PRWave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATDFollowing meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year interim analysis for potential accelerated approval based on AATD biomarkers WVE-006 (RNA editing) has potential to offer the AATD community a new standard-of-care treatment to protect the liver and lung with a safe and convenient therapy CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced alignment with the U.S. Food and Drug Administration (FDA) on key aspects of its planned registrational pathway for WVE-006, a
- PRWave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further DevelopmentCandidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing CAMBRIDGE, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that as part of the companies’ research collaboration, GSK has selected a candidate for a hepatology indication to transition into GSK’s development pipeline. This program was developed using Wave’s proprietary SpiNA design GalNAc-siRNA. "The advancement of this development candidate by GSK refle
- ANALYSTAnalyst resumed coverage on Wave Life SciencesAnalyst resumed coverage of Wave Life Sciences with a rating of Neutral
- PRWave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for ObesityWVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; preclinical data demonstrate Wave’s INHBE GalNAc-siRNA in combination with GLP-1 doubled weight loss compared with GLP-1 alone Maintenance clinical trial evaluating WVE-007’s ability to curtail weight regain after incretin cessation on track to initiate 2H 2026 CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the initiation of its Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in co
- PRWave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business OfficerDr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will join Wave’s executive team and lead business development, corporate development, and alliance management. "We are thrilled to welcome Dr. Vnuk to Wave in a newly created leadership role as we continue to advance our pipeline to the next stages of development. Monika’
- PRWave Life Sciences to Present at Cantor 2026 Global Healthcare ConferenceCAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on Thursday, September 10, 2026 at 9:45 a.m. ET. A live webcast of the presentation can be accessed by visiting "Investor Events" on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentat
- SECSEC Form EFFECT filed by Wave Life Sciences Ltd.EFFECT - Wave Life Sciences, Inc. (0001631574) (Filer)
- INSIDERDirector Wagner Heidi L sold $42,070 worth of shares (7,000 units at $6.01) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $5.97 (SEC Form 4)4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- INSIDERDirector Rawcliffe Adrian sold $67,183 worth of shares (12,700 units at $5.29) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- INSIDERDirector Tan Aik Na sold $2,596 worth of shares (432 units at $6.01) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,968 units (SEC Form 4)4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- INSIDERDirector Takanashi Ken sold $23,223 worth of shares (3,864 units at $6.01) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 20,079 units (SEC Form 4)4 - Wave Life Sciences, Inc. (0001631574) (Issuer)
- SECSEC Form 144 filed by Wave Life Sciences Ltd.144 - Wave Life Sciences, Inc. (0001631574) (Subject)
WVE FAQ
7 questionsWhat does Wave Life Sciences Ltd. do?
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD)...Where does WVE stock trade?
Wave Life Sciences Ltd. (WVE) is listed on NASDAQ.What sector and industry is WVE in?
Wave Life Sciences Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Wave Life Sciences Ltd. go public?
Wave Life Sciences Ltd. (WVE) completed its IPO in 2015.What are analysts saying about WVE?
Wave Life Sciences Ltd. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-10-16. Recent price targets range from $1000.00 to $3800.00.What companies are similar to WVE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare WVE side-by-side with any of them on Quantisnow.How can I track WVE on Quantisnow?
Quantisnow aggregates Wave Life Sciences Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WVE to receive live email and push alerts on every new disclosure.